Fecal Microbiota Transplantation and Emerging Treatments for Clostridium difficile Infection

2013 ◽  
Vol 26 (5) ◽  
pp. 498-505 ◽  
Author(s):  
Krista D. Gens ◽  
Ramy H. Elshaboury ◽  
Jessica S. Holt
Keyword(s):  
Health Care ◽  
Clostridium Difficile ◽  
Health Care Providers ◽  
Clostridium Difficile Infection ◽  
Fecal Microbiota Transplantation ◽  
Treatment Options ◽  
Fecal Microbiota ◽  
Care Providers ◽  
Efficacy And Safety ◽  
Emerging Treatments

Due to the increased incidence and recurrence of Clostridium difficile infection, health care providers are seeking new and alternative treatments to the standard antibiotic therapy. The objective of this article is to present a review on the background, microbiologic efficacy, clinical efficacy, and safety of fecal microbiota transplantation and to provide an overview of emerging treatment options currently under investigation. Emerging treatment options discussed include the use of monoclonal antibodies directed against toxins A and B, C difficile vaccination, and transplantation of nontoxigenic C difficile strains.

scholarly journals Fecal microbiota transplantation via colonoscopy in a dog with Clostridioides (Clostridium) difficile infection

2021 ◽  
Vol 51 (3) ◽  
Author(s):  
Amanda Nadia Diniz ◽  
Angélica da Costa Ferreira de Souza ◽  
Anelise Carvalho Nepomuceno ◽  
Sóstenes Apolo Correia Marcelino ◽  
Felipe Pierezan ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Nosocomial Infection ◽  
Stool Sample ◽  
Clostridium Difficile Infection ◽  
Antimicrobial Therapy ◽  
Recurrent Disease ◽  
Fecal Microbiota Transplantation ◽  
Treatment Options ◽  
Fecal Microbiota ◽  
Toxin Detection

ABSTRACT: In dogs, antimicrobial therapy for Clostridioides (Clostridium) difficile infection (CDI) is based solely on metronidazole, leaving limited treatment options in case of recurrent disease. Fecal microbiota transplantation (FMT) has been successfully used in humans with recurrent CDI, whereas the usefulness of this approach is largely unknown in dogs. In the present study, a dog with a chronic-recurring diarrhea was treated with FMT via colonoscopy. CDI was confirmed by A/B toxin detection and isolation of toxigenic C. difficile from ribotype 106, a strain also commonly associated with nosocomial infection in humans. The dog recovered well after the procedure and C. difficile was no longer isolated from its stool sample. The present research suggested that FMT could be a useful tool to treat recurrent CDI in dogs, corroborating the actual protocol in humans.

scholarly journals Clostridium difficile infection in patients after solid organ transplantations

2020 ◽  
Vol 74 ◽  
pp. 198-204
Author(s):  
Sylwia Dudzicz ◽  
Marcin Adamczak ◽  
Andrzej Więcek
Keyword(s):  
Clostridium Difficile ◽  
General Population ◽  
Immunosuppressive Therapy ◽  
Clostridium Difficile Infection ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Solid Organ ◽  
Proper Treatment ◽  
Efficacy And Safety ◽  
Antibiotic Associated Diarrhea

Clostridium difficile is the most common identified pathogen causing nosocomial and antibiotic-associated diarrhea. The incidence of Clostridium difficile infection (CDI) has increased over the last decades. The occurrence of severe and recurrent CDI is also more often recently observed. Patients after solid organs transplantation are more prone to Clostridium difficile infection that the general population. This is associated mainly with immunosuppressive therapy, more frequent hospitalizations and frequent antibiotic therapy. Due to the growing number of CDI, it is important to correctly diagnose this infection and to implement the proper treatment. The main drugs used to treat CDI are vancomycin and fidaxomicin. In the case of CDI recurrence, fecal microbiota transplantation remains to be considered. The rationale use of antibiotics and avoiding proton pump inhibitors may also prevent CDI. Results of recent observational study suggest that one of the probiotics – Lactobacillus plantarum 299v prevents CDI in patients during immunosuppressive therapy. The efficacy and safety of using probiotics in CDI prophylaxis in this group of patients requires, however, further studies.

scholarly journals Patient Perspectives on Fecal Microbiota Transplantation for Clostridium Difficile Infection

2016 ◽  
Vol 5 (2) ◽  
pp. 155-164 ◽  
Author(s):  
Caroline Zellmer ◽  
Travis J. De Wolfe ◽  
Sarah Van Hoof ◽  
Rebekah Blakney ◽  
Nasia Safdar
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Patient Perspectives
Sign in / Sign up

Export Citation Format

Share Document